Hideki Tsuji, Satoru Kawai, Toshiyuki Arai, Koutarou Hattori, Yukie Tashiro, Takashi Hiromatsu, Michihiko Narita, Shingo Kuze, Yasuhiro Kurumiya, Iwao Kitazono, Karine Rousseau, Hitoshi Kubota, Masahiko Osako, Eiji Sasaki, Norihiro Yuasa, Osamu Okochi, Masaki Sakamoto, Masahiko Fujino, Naomi Konishi, Hiroshi Hasagawa, Hiroaki Shibahara, Hiroshi Shirahama, Akinobu Kondo, Shinji Kondo, Michiyo Higashi, Yoshichika Okamoto, Suguru Yonezawa, Tatsuyoshi Yamamoto, Hideaki Suzuki, Surinder K. Batra, Seiya Yokoyama, Yu Sakai, Kazuhisa Shirai, and Takehito Kato
Background Mucins are implicated in survival in various cancers, but there have been no report addressed on survival in appendiceal carcinoma, an uncommon disease with different clinical and pathological features from those of other colon cancers. We aimed to investigate the clinical implications of expression of mucins in appendiceal carcinoma. Methods Expression profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6, MUC16 and MUC17 in cancer tissue were examined by immunohistochemistry in 108 cases of surgically resected appendiceal carcinoma. Results The following relationships of mucins with clinicopathologic factors were identified: MUC1 with positive lymphatic invasion (p = 0.036); MUC2 with histological type (mucinous carcinoma, p